Aktienanalyse zu Telomir Pharmaceuticals Inc (TELO)TELOTelomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. is a biotechnology company developing small-molecule therapeutics designed to target epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company's lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability. Telomir-1 is an oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease, and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Telomir Pharmaceuticals is currently not a strong buy due to its very low RSI of 18.086, indicating it is oversold, and a significant negative trend with a 1-year change of -38.99%. However, the potential upside is notable with an analyst price target of $4, suggesting a potential increase of over 330% from the current price of $0.92. The main risk is the company's ongoing losses, with a last earnings EPS reported at -0.79, which could continue to affect investor sentiment.